Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16940167 | 0.96 | CHRM2 (0.36) | SLC18A3SLC6A2SLC6A4SLC6A3CHRM2 | |
| SCHEMBL15434592 | 0.96 | CHRM2 (0.36) | SLC18A3SLC6A2SLC6A4SLC6A3CHRM2 | |
| SCHEMBL30390498 | 0.96 | CHRM2 (0.36) | SLC18A3SLC6A2SLC6A4SLC6A3CHRM2 | |
| SCHEMBL20596233 | 0.91 | CHRM2 (0.33) | SLC18A3SLC6A2SLC6A4SLC6A3CHRM2 | |
| SCHEMBL20596379 | 0.91 | CHRM2 (0.33) | SLC18A3SLC6A2SLC6A4SLC6A3CHRM2 | |
| SCHEMBL25970852 | 0.83 | HRH3 (0.32) | SLC6A2SLC6A3 | |
| SCHEMBL25970892 | 0.81 | SLC6A4 (0.38) | SLC6A2SLC6A4SLC6A3OPRL1 | |
| SCHEMBL25988334 | 0.80 | SLC6A4 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19375703 | 0.80 | CHRM2 (0.40) | SLC18A3SLC6A2SLC6A4SLC6A3CHRM2 | |
| SCHEMBL19375446 | 0.80 | CHRM2 (0.40) | SLC18A3SLC6A2SLC6A4SLC6A3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | SLC18A3 2260/4885SLC6A2 2493/4885SLC6A4 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.